

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

<https://marketpublishers.com/r/CE447D8BE52EN.html>

Date: January 2020

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: CE447D8BE52EN

Abstracts

This report can be delivered to the clients within 48 Hours

'Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020' report by DelveInsight offers comprehensive insights on marketed and Phase III products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) including their detailed product profiles.

Additionally, the report also highlights the future competitive landscape for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics. Depending on information availability comprehensive coverage of the following for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) descriptive marketed product profiles for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2023 for each product.

Global API Manufacturers of marketed products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) coverage of API manufacturers for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers

name along with their location Emerging Phase III products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) descriptive Phase III product profiles for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2023.

Report Methodology

The report provides insights into:

Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment

Comparative analysis of the marketed and emerging products

Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities

Global sales of the marketed therapies from 2012-2023 is covered in the report

Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India

List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Analytical Perspective by DelveInsight

In-depth Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Commercial Assessment of Marketed Products

This report provides an in-depth commercial assessment of marketed products, which comprises the details of collaborations, licensing, acquisition - deal value trends, patent and global sales.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Assessment of Emerging Products

The report comprises of comparative clinical assessment of products by development stage, route of administration and molecule type across this indication.

SCOPE OF THE REPORT

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report provides a comprehensive understanding of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed and emerging (Phase III) products

Access to API manufacturers details for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) marketed drugs to devise API procurement strategy for generic development

Plan developmental timelines around marketed drug patents for the major markets- US and EU

Understand current and future growth of marketed Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics through their historical and forecasted sales

Identify and analyze future sales trends of emerging Phase III Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics through their forecasted sales

Identify the products attributes and use it for target finding, drug repurposing, and precision medicine

Identify and plan ahead for prospective emerging players and their products for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

REPORT HIGHLIGHTS

In the coming years, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is set to change due to the extensive research in this field, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

There are many companies involved in developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Launch of emerging therapies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) will significantly impact the market.

A better understanding of target mechanism will also contribute to the development of novel therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Our in-depth analysis of the marketed and late-stage pipeline assets comparative analysis of the products. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

KEY QUESTIONS

What are the current treatment options available based on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

How many companies are developing therapies for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

What are the principal therapies developed by these companies in the industry?

How many therapies are developed by each company for Chronic Inflammatory

Demyelinating Polyneuropathy (CIDP) to treat disease condition?

How many emerging therapies are in late stage of development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

What is the trend of historical and forecasted sales of the marketed products from the period 2012-2023?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapies?

Which are the API manufacturers across United States, Europe, China and India for the marketed therapies?

How many patents are granted to the marketed therapies of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?

How late-stage emerging therapies are distinguished on the basis of their mechanism of action, route of administration and molecule type?

Contents

1. REPORT INTRODUCTION

2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)

- 2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Symptoms
- 2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Causes
- 2.3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Types
- 2.4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Risk Factors / Complications
- 2.5. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pathophysiology
- 2.6. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Diagnosis
- 2.7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment

3. COMPARATIVE ANALYSIS OF MARKETED AND EMERGING PRODUCTS

3.1. Marketed Products

3.1.1. Drug A: Company

- 3.1.1.1. Product Description
- 3.1.1.2. Regulatory Milestones
- 3.1.1.3. Product Development Activities
 - 3.1.1.3.1. General Description Table
- 3.1.1.4. Global Sales
- 3.1.1.5. Global API Manufacturers for Drug A
 - 3.1.1.5.1. United States
 - 3.1.1.5.2. Europe
 - 3.1.1.5.3. China
 - 3.1.1.5.4. India

3.1.2. Drug B: Company

- 3.1.2.1. Product Description
- 3.1.2.2. Regulatory Milestones
- 3.1.2.3. Product Development Activities
 - 3.1.2.3.1. General Description Table
- 3.1.2.4. Global Sales
- 3.1.2.5. Global API Manufacturers for Drug B
 - 3.1.2.5.1. United States
 - 3.1.2.5.2. Europe
 - 3.1.2.5.3. China

3.1.2.5.4. India

Complete details in the report

3.1.3. Emerging Therapies - Late Phase

3.1.3.1. List of Phase III drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

4. APPENDIX

5. REPORT METHODOLOGY

5.1. Secondary Research

5.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1 : List of Marketed and Emerging Products
- Table 2: Drug A Annual Global Sales from 2012-2023 (in USD million)
- Table 3: API Manufacturers for Drug A Region wise
- Table 4: API Manufacturers for Drug A for the United States
- Table 5: API Manufacturers for Drug A for Europe
- Table 6:/ API Manufacturers for Drug A for India
- Table 7: API Manufacturers for Drug A for China
- Table 8: Drug B Annual Global Sales from 2012-2023 (in USD million)
- Table 9: API Manufacturers for Drug B Region wise
- Table 10: API Manufacturers for Drug B for the United States
- Table 11: API Manufacturers for Drug B for Europe
- Table 12: API Manufacturers for Drug B for India
- Table 13: API Manufacturers for Drug B for China
- Table 14: Drug C Annual Global Sales from 2014-2023 (in USD million)
- Table 15: API Manufacturers for Drug C Region wise
- Table 16: API Manufacturers for Drug C for the United States
- Table 17: API Manufacturers for Drug C for Europe
- Table 18: API Manufacturers for Drug C for India
- Table 19: API Manufacturers for Drug C for China
- Table 20: Drug D, Annual Global Sales from 2013-2023 (in USD million)
- Table 21: API Manufacturers for Drug D Region wise
- Table 22: API Manufacturers for Drug D for the United States
- Table 23: API Manufacturers for Drug D for Europe
- Table 24: API Manufacturers for Drug D for India
- Table 25: API Manufacturers for Drug D for China
- Table 26: Drug E Annual Global Sales from 2014-2023 (in USD million)
- Table 27: API Manufacturers for Drug E Region wise
- Table 28: API Manufacturers for Drug E for the United States
- Table 29: API Manufacturers for Drug E for Europe
- Table 30: API Manufacturers for Drug E for India
- Table 31: API Manufacturers for Drug E for China
- Table 32: List of Phase III drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

List Of Figures

LIST OF FIGURES

- Figure 1: Comparative Analysis of Marketed and Emerging Products
- Figure 2: Drug A, Annual Global Sales from 2012-2023 (in USD million)
- Figure 3: API Manufacturers for Drug A Region wise
- Figure 4: Drug B, Annual Global Sales from 2012-2023 (in USD million)
- Figure 5: API Manufacturers for Drug B Region wise
- Figure 6: Drug C, Annual Global Sales from 2014-2023 (in USD million)
- Figure 7: API Manufacturers for Drug C Region wise
- Figure 8: Drug D, Annual Global Sales from 2011-2023 (in USD million)
- Figure 9: API Manufacturers for Drug D Region wise
- Figure 10: Drug E, Annual Global Sales from 2014-2023 (in USD million)
- Figure 11: API Manufacturers for Drug E Region wise

I would like to order

Product name: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Product link: <https://marketpublishers.com/r/CE447D8BE52EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE447D8BE52EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

